COGT - Cogent Biosciences, Inc. Stock Price, Fair Value and News

$7.84+0.04 (+0.51%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

COGT Price Action

Last 7 days

-3.8%

Last 30 days

-13.7%

Last 90 days

-28.6%

Trailing 12 Months

42.6%

COGT RSI Chart

COGT Valuation

Market Cap

866.0M

Price/Earnings (Trailing)

-3.57

Price/Sales (Trailing)

145.53

Price/Free Cashflow

-4.51

COGT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

COGT Fundamentals

COGT Revenue

Revenue (TTM)

7.9M

COGT Earnings

Earnings (TTM)

-242.3M

Earnings Growth (Yr)

-27.54%

Earnings Growth (Qtr)

-19.82%

COGT Profitability

Return on Equity

-77%

Return on Assets

-63.1%

Free Cashflow Yield

-22.18%

COGT Investor Care

Shares Dilution (1Y)

28.26%

Diluted EPS (TTM)

-2.48

COGT Alerts

Point72 Asset Management, L.P. reported owning 9.9% of COGT [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	26.5M	23.9M	23.2M	7.9M
2019	10.6M	12.0M	11.0M	22.5M
2018	8.8M	8.3M	8.1M	9.7M
2017	0	0	0	8.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Andrew R. Robbins M.B.A.
WEBSITE	cogentbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	138

Cogent Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Cogent Biosciences, Inc.? What does COGT stand for in stocks?

COGT is the stock ticker symbol of Cogent Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cogent Biosciences, Inc. (COGT)?

As of Fri Dec 20 2024, market cap of Cogent Biosciences, Inc. is 866.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COGT stock?

You can check COGT's fair value in chart for subscribers.

Is Cogent Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether COGT is over valued or under valued. Whether Cogent Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Cogent Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COGT.

What is Cogent Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, COGT's PE ratio (Price to Earnings) is -3.57 and Price to Sales (PS) ratio is 145.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COGT PE ratio will change depending on the future growth rate expectations of investors.